Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?
Saved in:
| Title: | Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important? |
|---|---|
| Authors: | Vitale P; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy., De Falco V; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy., Addeo R; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy. |
| Source: | Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jul; Vol. 24 (7), pp. 481-484. Date of Electronic Publication: 2024 May 13. |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-8328 |
|---|---|
| DOI: | 10.1080/14737140.2024.2354772 |
